Medeze scoops prestigious industry award for stem cell innovation
MEDEZE Group Public Company Limited hit a high note in the world of regenerative medicine, bagging the coveted ACES Award for Industry Champions of the Year.
This accolade shines a spotlight on the firm’s monumental strides in stem cell banking across Southeast Asia, celebrating its impressive evolution from Bangkok Stem Cell in 2010 to Thailand’s top mesenchymal stem cell bank today.
Boasting some of the region’s most cutting-edge stem cell labs, MEDEZE is not one to rest on its laurels. With Class 100 Cleanroom certification from the prestigious National Environmental Balancing Bureau, USA (NEBB), and rigorous adherence to the American Association for the Advancement of Blood & Biotherapies (AABB) standards, they’re clearly a force to be reckoned with, said a MEDEZE Group spokesperson.
“This recognition reflects our unwavering commitment to pushing the boundaries of longevity science. We’ve consistently invested in cutting-edge technology and maintained rigorous quality protocols to ensure we deliver the highest standards of care to our clients.”
MEDEZE has shattered norms with its pioneering breakthroughs, including Thailand’s first storage of mesenchymal stem cells (MSC) for umbilical cord tissue and the groundbreaking world debut of adipose tissue storage. Their innovations offer new hope for treating an array of conditions, all the way from heart disease to neurodegenerative disorders.
The company’s sci-tech repertoire doesn’t stop there. With its pioneering NK cell immunotherapy programme—crafted with the expertise of Japanese scientists Dr. Junichi Masuyama and Dr. Sanehiko Fujita—MEDEZE enhances natural immune responses, tackling chronic illnesses and cancer.
With operations spanning nine countries, MEDEZE has partnered with a staggering 206 hospitals and clinics in Thailand, including the illustrious Bangkok Hospital and Bumrungrad Hospital. Its influence rings out across Europe, Australia, and New Zealand, delivering state-of-the-art medical solutions worldwide.
Through the Bangkok Stem Cell Foundation, founded in 2015, MEDEZE is also championing the cause of public health education, and spreading the word about the potential of stem cell therapy. And with a rock-solid 35.46% net profit margin achieved by the third quarter of 2023, they’ve expertly balanced business triumph with social responsibility.
The ACES Award adds another feather to MEDEZE’s already crowded cap, joining other esteemed accolades like the Frost & Sullivan Southeast Asia Company of the Year Award. With such laurels, MEDEZE cements its status as a trailblazer in the domain of stem cell banking services, steadfast in its quest to push the frontiers of longevity science even further, reported Bangkok Post
As the global stem cells and regenerative medicine market rockets skyward, MEDEZE Group stands primed at the cutting edge—ready to shape the future of healthcare with its stellar stem cell banking services and pioneering therapies.
What Other Media Are Saying
- PR Newswire reports Medeze Group’s recognition as Southeast Asia’s Company of the Year by Frost & Sullivan due to its innovative stem cell banking services, enhancing health outcomes and longevity through advanced techniques. (read more)
- ACES Awards highlights Medeze’s pioneering role in regenerative medicine, showcasing its extensive network across Asia-Pacific and commitment to sustainability, innovation, and corporate responsibility in advancing public health initiatives. (read more)
Frequently Asked Questions
Here are some common questions asked about this news
Why is MEDEZE’s approach to stem cell technology considered groundbreaking?
MEDEZE’s pioneering storage services for umbilical cord and adipose tissue have opened new treatment avenues for critical conditions.
How does MEDEZE’s NK cell program potentially change cancer treatment?
By enhancing immune response, this program could revolutionize treatment for chronic illnesses and cancer, offering more effective therapies.
What if MEDEZE’s innovations in stem cell banking become a global standard?
It could lead to widespread advancements in regenerative medicine, elevating healthcare quality and longevity worldwide.
How does MEDEZE balance financial success with social responsibility?
Through strong net profit margins and initiatives like the Bangkok Stem Cell Foundation, MEDEZE aligns business success with public health education.
What implications does MEDEZE’s global reach have on the future of healthcare?
With operations in multiple countries, MEDEZE is positioned to significantly influence healthcare evolution through advanced medical solutions.
